Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 4, 2009, Pages 412-416

  Honnorat, J ^a,b,c,i   Cartalat Carel, S ^a   Ricard, D ^d   Camdessanche, J Ph ^a,b,e   Carpentier, A F ^a,f   Rogemond, V ^a,b   Chapuis, F ^a,c   Aguera, M ^b   Decullier, E ^a,c   Duchemin, A M ^g   Graus, F ^h   Antoine, J C ^a,b,d  

^a HOSPICES CIVILS DE LYON   (France)

^b INSERM   (France)

^c UNIVERSITÉ LYON 1   (France)

^d University of Paris Descartes   (France)

^e SERVICE DE NEUROLOGIE   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g OHIO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ HÔPITAL NEUROLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CRMP5 ANTIBODY; CV2 ANTIBODY; HU ANTIBODY; UNCLASSIFIED DRUG; CANCER ANTIBODY; DPYSL5 PROTEIN, HUMAN; HU ANTIGEN; NERVE PROTEIN;

AGE; ARTICLE; BRAIN STEM; CEREBELLAR ATAXIA; CHOREA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSAUTONOMIA; EATON LAMBERT SYNDROME; ENCEPHALITIS; FEMALE; HUMAN; IMMUNITY; LUNG SMALL CELL CANCER; MALE; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; NEUROMUSCULAR JUNCTION DISORDER; NEUROPATHY; OPSOCLONUS; PARANEOPLASTIC NEUROPATHY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANKIN SCALE; SEX RATIO; SURVIVAL TIME; THYMOMA; ADULT; AGED; BRAIN TUMOR; IMMUNOLOGY; MIDDLE AGED; ONSET AGE; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; SURVIVAL;

ADULT; AGE OF ONSET; AGED; ANTIBODIES, NEOPLASM; BRAIN NEOPLASMS; FEMALE; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NERVOUS SYSTEM DISEASES; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; PROGNOSIS; SURVIVAL ANALYSIS; THYMOMA;

EID: 64749091877     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2007.138016     Document Type: Article

References (22)

1. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135-40.
2. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004;56:715-19.
3. Antoine JC, Honnorat J, Vocanson C, et al. Posterior uveitis, paraneoplastic encephalomyelitis and auto-antibodies reacting with developmental protein of brain and retina. J Neurol Sci 1993;117:215-23.
4. Honnorat J, Antoine JC, Derrington E, et al. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996;61:270-8.
5. Honnorat J, Aguera M, Zalc B, et al. POP66, a paraneoplastic encephalomyelitisrelated antigen, is a marker of adult oligodendrocytes. J Neuropathol Exp Neurol 1998;57:311-22.
6. Honnorat J, Antoine JC, Belin MF. Are the "newly discovered'' paraneoplastic anticollapsin response-mediator protein 5 antibodies simply anti-CV2 antibodies? Ann Neurol 2001;50:688-91
7. Rogemond V, Honnorat J. Anti-CV2 autoantibodies and paraneoplastic neurological syndromes. Clin Rev Allergy Immunol 2000;19:51-9.
8. Ricard D, Rogemond V, Charrier E, et al. Isolation and expression pattern of human Unc-33-like phosphoprotein 6/collapsin response mediator protein 5 (Ulip6/CRMP5): coexistence with Ulip2/CRMP2 in Sema3a-sensitive oligodendrocytes. J Neurosci 2001;21:7203-14.
9. Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146-54.
10. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124:1138-48.
11. Graus F, Vega F, Delattre J, et al. Effect of plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal antibodies. Neurology 1992;42:536-40.
12. Denny-Brown D. Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiatry 1948;11:73-87.
13. Dalmau J, Furneaux HM, Rosenblum MK, et al. Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology 1991;41:1757-64.
14. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998;50:652-7.
15. Antoine JC, Honnorat J, Camdessanche JP, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001;49:214- 21.
16. Camdessanche JP, Antoine JC, Honnorat J, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 2002;125:166-75.
17. Thambisetty MR, Scherzer CR, Yu Z, et al. Paraneoplastic optic neuropathy and cerebellar ataxia with small cell carcinoma of the lung. J Neuroophthalmol 2001;21:164-7.
18. Vernino S, Tuite P, Adler CH, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002;51:625-30.
19. Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003;54:38-50.
20. Samii A, Dahlen DD, Spence AM, et al. Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody. Mov Disord 2003;18:1556-8.
21. Rogemond V, Cavillon G, Aguera M, et al. Immunohistochemistry is necessary to characterize anti-CV2/CRMP5 antibodies associated with paraneoplastic neurological syndromes. J Neuroimmunol 2006;174(Suppl):200-1S.
22. Camdessanché J-P, Lassabliere F, Meyronnet D, et al. Expression of the onconeuronal CV2/CRMP5 antigen in thymus and thymoma. J Neuroimmunol 2006;174:168-73.